Advertisement
Singapore markets close in 2 hours 15 minutes
  • Straits Times Index

    3,280.58
    -12.55 (-0.38%)
     
  • Nikkei

    37,628.48
    -831.60 (-2.16%)
     
  • Hang Seng

    17,222.04
    +20.77 (+0.12%)
     
  • FTSE 100

    8,040.38
    -4.43 (-0.06%)
     
  • Bitcoin USD

    64,214.14
    -2,545.49 (-3.81%)
     
  • CMC Crypto 200

    1,391.03
    +8.46 (+0.61%)
     
  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     
  • Dow

    38,460.92
    -42.77 (-0.11%)
     
  • Nasdaq

    15,712.75
    +16.11 (+0.10%)
     
  • Gold

    2,331.40
    -7.00 (-0.30%)
     
  • Crude Oil

    82.89
    +0.08 (+0.10%)
     
  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     
  • FTSE Bursa Malaysia

    1,570.31
    -1.17 (-0.07%)
     
  • Jakarta Composite Index

    7,158.01
    -16.53 (-0.23%)
     
  • PSE Index

    6,586.90
    +14.15 (+0.22%)
     

Better Buy: Pfizer vs. Bristol Myers Squibb

Better Buy: Pfizer vs. Bristol Myers Squibb

Pfizer (NYSE: PFE) will look like a much different company within a few months as it spins off Upjohn and merges the unit with Mylan. Bristol Myers Squibb (NYSE: BMY) is still integrating Celgene after acquiring the biotech in November. Both Pfizer and BMS have seen their stocks plunge close to 30% this year then make strong rebounds.